Denmark's Genmab is rolling right along with breakthrough-designated daratumumab for double refractory multiple myeloma, hitting a milestone in Phase II development and triggering a $22 million payout from collaborator Johnson & Johnson.
It's bad news for Johnson and Johnson's Ethicon division in its ongoing vaginal mesh saga: The company paid out $11.1 million to settle one of the first of many cases to go to court over its transvaginal mesh products, Lawyers and Settlements reported.
GlaxoSmithKline announced today that bottles of its alli over-the-counter weight-loss drug were tampered with, and warned consumers to look out for suspect packages.
In February, a U.S. magistrate judge ruled that J&J wrongly eliminated thousands of key documents relating to the legal fight over allegations that it sold faulty vaginal mesh implants that harmed women, due to apparent negligence. Now, a patient advocacy group is demanding a federal investigation into the matter.
Last week, Johnson & Johnson became the first Big Pharma company to appoint a chief design officer in Ernesto Quinteros. But while the move may have helped the New Jersey company blaze a pharma trail, some, like IDEA Pharma CEO Mike Rea, say it's long overdue.
Johnson & Johnson's Janssen, which has struggled to maintain ready supplies of its ovarian cancer treatment Doxil, has released a new lot of the popular drug. The injectable cancer med was produced through an "alternative manufacturing approach" in which the now-closed Ben Venue plant in Ohio made the bulk product and another manufacturer finished it off.
In 2013, a number of outside forces hammered the med tech industry. While things could have been better, most of the top 10 companies in the sector still enjoyed moderate year-over-year revenue gains.
Rheumatoid arthritis has become a key therapeutic area for Johnson & Johnson, with Remicade and Simponi generating sales of $7.6 billion by treating the disease and other autoimmune disorders last year. To maintain its position, J&J subsidiary Janssen is working with the San Diego Supercomputer Center on whole genome sequence analysis.
The horse race for oral treatments of chronic hepatitis C entered another turn today as the European Union recommended approval of Olysio, the Johnson & Johnson and Medivir entry in the high-stakes derby, Bloomberg reports.
The U.K.'s National Institute for Health and Care Excellence has come around on Johnson & Johnson's Velcade as a first-line treatment for the blood cancer multiple myeloma. It approved the drug for the new use today, four months after initially saying it was unconvinced the benefits of the drug outweighed its costs.